-

MetLife Appoints Two Experienced Leaders to Board of Directors

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that Dan Glaser and Michelle Seitz were elected to its Board of Directors (the “Board”), effective immediately. Both leaders bring significant leadership and business experience to their roles.

“Michelle and Dan embody the kind of strategic leadership, global perspective, and established expertise that will help guide MetLife in our New Frontier strategy.”

Share

Glaser, currently an operating partner at the private investment firm CD&R, has held senior positions in commercial insurance and insurance brokerage for more than 40 years, including serving for a decade as president and CEO of Marsh McLennan (MMC). He was also president and chief operating officer of Willis Risk Solutions and held senior roles at AIG, including leading its U.K. and Ireland operations. For 10 years, Glaser served as chairman of the U.S. Federal Advisory Committee on Insurance.

Seitz brings more than 30 years of investment management experience to the Board, most recently serving as chair and CEO of Russell Investments and CEO of investment bank, William Blair, before that. She is the founder and CEO of MeydenVest Partners LLC, a strategic advisory firm providing capital and counsel to high potential companies. Seitz also currently serves as an independent director of MSCI Inc. and Sana Biotechnology, Inc.

“We are pleased to welcome Michelle and Dan to MetLife’s Board of Directors,” said R. Glenn Hubbard, chairman of MetLife, Inc. “Together, they bring deep leadership experience and industry expertise that will further enable MetLife to deliver for its shareholders and all stakeholders.”

“Michelle and Dan embody the kind of strategic leadership, global perspective, and established expertise that will help guide MetLife in our New Frontier strategy,” said Michel Khalaf, MetLife President and CEO. “Dan’s decades of experience shaping the insurance industry and Michelle’s proven track record in investment management make them exceptional additions to our Board.”

New board member biographies:

Dan Glaser is a veteran insurance executive with more than 40 years of global leadership experience across the commercial insurance and brokerage sectors. He is currently an operating partner at the private investment firm CD&R. He served for a decade as president and CEO of Marsh McLennan (MMC) and held senior roles at MMC, including chairman and CEO of Marsh, interim CEO of Mercer, and group president and chief operating officer. He also held senior roles at Willis Risk Solutions and AIG, leading businesses across the U.S., Europe, and the Middle East. Glaser also chaired the U.S. Federal Advisory Committee on Insurance for a decade and was appointed an honorary Most Excellent Officer of the Order of the British Empire (OBE) in recognition for contributions to U.K.–U.S. trade and investment. Glaser holds a bachelor’s degree from Ohio Wesleyan University and completed the Advanced Management Program at Harvard Business School.

Michelle Seitz is a global business and investment management leader with more than three decades of experience transforming and scaling complex financial organizations. She served as chair and CEO of Russell Investments and CEO of William Blair, following a career spanning leadership roles across major global investment platforms. She is the founder and CEO of MeydenVest Partners LLC and serves as an independent director of MSCI Inc., Sana Biotechnology, and the Fred Hutch Cancer Center. Seitz is also recognized among the industry’s most influential leaders by Barron’s and American Banker. She holds a Bachelor of Science in Accounting from Indiana University’s Kelley School of Business and is a Chartered Financial Analyst.

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit www.metlife.com.

Contacts

For Media:
Jane Slusark
(347) 989-5477
Jane.Slusark@metlife.com

For Investors:
John Hall
(212) 578-7888
John.A.Hall@metlife.com

MetLife, Inc.

NYSE:MET

Release Versions
Hashtags

Contacts

For Media:
Jane Slusark
(347) 989-5477
Jane.Slusark@metlife.com

For Investors:
John Hall
(212) 578-7888
John.A.Hall@metlife.com

Social Media Profiles
More News From MetLife, Inc.

MetLife Increases Common Stock Dividend by 4.4%

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that its board of directors has declared a second quarter 2026 common stock dividend of $0.5925 per share, an increase of 4.4% from the first quarter common stock dividend of $0.5675 per share. MetLife has increased its common stock quarterly dividend at an 8.1% compound annual growth rate since 2011. The dividend will be payable on June 9, 2026, to shareholders of record as of May 12, 2026. “We are pleased to increase our com...

Majority of Employers Support Embedding Guaranteed Lifetime Income Options into Workplace Retirement Plans, MetLife Poll Finds

NEW YORK--(BUSINESS WIRE)--Released today, MetLife’s 2026 Lifetime Income Poll finds that defined contribution (DC) plan sponsors increasingly support approaches that help workers convert retirement savings into a dependable income stream. Nine in 10 DC plan sponsors (90%) say the core purpose of a DC plan should be to serve as an income source during retirement, signaling broad employer alignment around lifetime income options in 401(k) plans and strong engagement with the policy conversation...

MetLife Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has received notice of an unsolicited mini-tender offer by Potemkin Limited (“Potemkin”) to purchase up to 100,000 shares of MetLife, Inc. common stock from MetLife shareholders. The offer is for approximately 0.02 percent of MetLife shares of common stock outstanding as of March 31, 2026. Potemkin’s offer price of $44.20 per share is approximately 41.35 percent lower than the $75.36 closing price of MetLife common sto...
Back to Newsroom